Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Empiriko, a clinical intelligence company, and CreaGen Biosciences, a drug discovery service company and science research incubator, have announced a partnership agreement under which CreaGen will provide chemistry expertise and modern laboratory facilities for standardizing and scaling Empiriko's chemosynthetic liver technology (Biomimiks).
Subscribe to our email newsletter
By capitalizing on CreaGen’s chemistry expertise and state-of-the-art laboratory facility, Empiriko is validating methodologies for its transformative Biomimiks technology. Now pharmaceutical customers, for the first time, can use a chemistry-based system to rapidly and accurately predict and confirm metabolism patterns, pathways and profiles for small molecule therapeutics.
This announcement comes just a week after Empiriko’s official launch: Empiriko Brings Game-changing Technology to Drug Discovery and Clinical Research Industry.
Empiriko chief scientific officer Mukund Chorghade noted the company is thrilled to be working with CreaGen, especially given their extensive experience in medicinal chemistry and drug discovery.
"This partnership enables us to share brainpower, while tapping into CreaGen’s expansive facilities for parallel chemistry, spectroscopy and chromatography," Chorghade added.
CreaGen Biosciences chairman and CEO Dr Raj Rajur noted the company is excited to be partnering with the Empiriko team and to have this special opportunity to support their Biomimiks technology.
"We are confident that this chemistry-based technology has the potential for changing the way pharmaceutical companies predict, confirm and quantify the accurate formation of drug metabolites and their likely clinical impact. This partnership enables us to play a strategic role in taking this technology to the next level of commercialization," Dr Rajur added.